Skip to content
sellWeak cluster of 210b5-1 plan

Rosty Raykov sold $78k of FENC

director at FENNEC PHARMACEUTICALS INC.. 10,312 shares at an average of $7.60, traded Jan 2, 2026, filed Jan 5, 2026.

Warning score
2
Value
$78k
10,312 shares
Holdings after
88,020
-10% from before
From 52-week low
+53%
low $5.01, close $7.68
From 52-week high
-22%
high $9.88, as of Jan 2, 2026

Score components

  • Role
    Director
    +15
  • Trade size
    $78k at market
    +9
  • Share of holdings sold
    Sold 10% of holdings
    +5
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +5.9%, 3m -14.4%, 6m +42.5%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

FENCOct 9, 2026 · close 10.71
Since filing Jan 5, 2026: +42.8%SPY +14.1% · excess +28.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001468316-26-000002, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 31, 2025AGrant or award
Common shares10b5-1
+5,208$0.00$082,734Jan 5, 2026
Jan 2, 2026MOption exercise
Common shares10b5-1
+15,598$2.45$38k98,332Jan 5, 2026
Jan 2, 2026SOpen-market sale
Common shares10b5-1
-10,312$7.60$78k88,020Jan 5, 2026
Jan 2, 2026MOption exercise
Stock Optionsderivative10b5-1
-15,598$2.45$38k1,618,586Jan 5, 2026

Related signals

Other insiders at FENNEC PHARMACEUTICALS INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
19Weak
FENCsell 210b5-1
FENNEC PHARMACEUTICALS INC.
Marco Maria Brughera
director
$160k
15,545 shares
-100%
13Weak
FENCsell 310b5-1
FENNEC PHARMACEUTICALS INC.
Rosty Raykov
other
$121k
10,000 shares
-7%
28Weak
FENCsell 210b5-1
FENNEC PHARMACEUTICALS INC.
Robert Andrade
CHIEF FINANCIAL OFFICER
$884k
75,000 shares
-26%
0Weak
FENCsell10b5-1
FENNEC PHARMACEUTICALS INC.
Rosty Raykov
director
$94k
9,747 shares
-7%
0Weak
FENCsell 210b5-1
FENNEC PHARMACEUTICALS INC.
Chris A Rallis
director
$59k
8,346 shares
-12%
0Weak
FENCsell 210b5-1
FENNEC PHARMACEUTICALS INC.
Rosty Raykov
director
$70k
10,781 shares
-8%
0Weak
FENCsell10b5-1
FENNEC PHARMACEUTICALS INC.
Rosty Raykov
director
$69k
10,946 shares
-9%
0Weak
FENCsell10b5-1
FENNEC PHARMACEUTICALS INC.
Rosty Raykov
director
$84k
10,079 shares
-9%
0Weak
FENCsell10b5-1
FENNEC PHARMACEUTICALS INC.
Rosty Raykov
director
$80k
10,349 shares
-10%
55Moderate
FENCsell 2
FENNEC PHARMACEUTICALS INC.
Southpoint Capital Advisors LP
owner
$7.5M
1,000,000 shares
-27%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.